LONDON – A head-to-head study funded by the UK Department of Health has found Avastin and Lucentis are equally effective and safe in treating wet age-related macular degeneration (AMD), and that using Avastin off-label in this indication would save the National Health Service £84.5 million (US$136.9 million) per year.